EP Patent

EP4114401A1 — Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Assigned to Incyte Corp · Expires 2023-01-11 · 3y expired

What this patent protects

The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

USPTO Abstract

The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

Drugs covered by this patent

Patent Metadata

Patent number
EP4114401A1
Jurisdiction
EP
Classification
—
Expires
2023-01-11
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.